
Benefits of Continuing Subcutaneous Daratumumab After Initial Quad Therapy: Pieter Sonneveld, MD, PhD
Projections of long-term progression-free survival (PFS) in patients with multiple myeloma treated with subcutaneous daratumumab (Darzalex Faspro; Johnson & Johnson) plus bortezomib, lenalidomide, and dexamethasone (VRd) support the quadruplet regimen …